Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration Read more about Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration
European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia Read more about European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies Read more about Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies
European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma Read more about European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research Read more about Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research
Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab Read more about Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab
Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015 Read more about Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015
Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis Read more about Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide Read more about FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide
Amgen To Present At The Credit Suisse 24th Annual Healthcare Conference Read more about Amgen To Present At The Credit Suisse 24th Annual Healthcare Conference
